The move comes even as India's drug regulator has extended Covishield's shelf life from six to nine months from its manufacturing date.
The expert committee sought more information from Serum Institute regarding the Oxford-AstraZeneca vaccine.
The global trials were halted after a study participant suffered a 'potentially unexplained illness, reports Sohini Das.
The nature of the adverse reaction and when the development took place were not initially clear, although the participant is expected to recover, said an individual familiar with the matter.
The Oxford/AstraZeneca vaccine is also being produced as part of a tie-up by the Serum Institute of India.
The DCGI also directed Serum Institute of India to increase the safety monitoring of the subjects already vaccinated as part of the trial, and submit the plan and report.
Apart from making efforts to meet the requirements of India, the company is also trying its best to balance the needs of the rest of the world, he added.
Sukanya Verma lists her 15 favourite Hindi songs of 2022 in no particular order.
In the next two weeks, the United States will detail plans to equitably distribute about 80 million (8 crore) COVID-19 vaccine doses globally without 'political requirements' of those receiving them, Secretary of State Antony Blinken has said.
"The vaccination schedule is considered complete 28 days after the administration of a dose for Janssen vaccine and 7 days after administration of a second dose for other vaccines (Pfizer / Comirnaty, Moderna, AstraZeneca/Vaxzevria/Covishield)," the statement added.
What the UK is getting out of the Serum Institute is what India is losing. And the responsibility of the Indian State ought to have been to dictate where Serum Institute's vaccine doses should go, argues Ambassador M K Bhadrakumar.
Poonawalla said booster vaccines have no demand as there is general lethargy among people and also because they are fed up with the pandemic.
However, in two different dose regimens, the vaccine's efficacy was 90 per cent in one and 62 per cent in the other.
Canada's Eugenie Bouchard, on a comeback trail from injury, began her campaign in the tournament with a 7-5. 6-2 win over Joanne Zuger of Switzerland. She was joined in the second round by compatriot and seventh-seed Rebecca Marino.
Australia's medicines and medical devices regulator on Monday formally recognised India's Covaxin, a vaccine against the coronavirus as the country's border was reopened for the first time in nearly 20 months.
50 lakh doses of 'Covishield' vaccine earmarked by the Serum Institute for export to the United Kingdom have now been made available for the inoculation of 18-44 age group in 21 states/UTs in India, amid a surge in COVID-19 cases, official sources said.
The UK government is under increasing pressure on Monday to review its COVID-19 vaccine protocol in place for travellers from India, after its updated rules effective from next month failed to recognise Indian vaccines under an expanded list of countries.
The economics and pricing of the Covishield vaccines and the government's own decision to pay higher prices raise more than a few questions, observes Prosenjit Datta.
From scanning hospital entrants to disinfecting hospital areas and floors, robots are being roped in for tasks considered high-risk, says Peerzada Abrar.
The WHO said the four current 'Variants of Concern' being monitored closely - Alpha, Beta, Gamma and Delta - are widespread and have been detected in all WHO regions.
The show-cause notice was issued following reports that human trials of the most promising COVID-19 vaccine candidate, being developed by the University of Oxford, have been put on hold after a United Kingdom participant had an adverse reaction to it.
November has some of the biggest movies and Web series coming up for release.
A village gets electricity after 75 years. A rare bird rescued. Why Kashmiris love Harisa. Do watch these interesting videos.
The New York Times on Tuesday said Covaxin works by teaching the immune system to make antibodies against the SARS-CoV-2 coronavirus. The antibodies attach to viral proteins, such as the so-called spike proteins that stud its surface.
The Oxford vaccine, which also has a tie-up with the Serum Institute of India, is expected to win approval in the UK before Thursday, speeding up the provision of the jab to the most vulnerable groups.
A technical advisory group of the World Health Organisation was on Tuesday reviewing data on Covaxin for the emergency use listing of India's indigenously-made vaccine and it could pronounce its decision within the next 24 hours or so, a spokesperson said.
The move towards indigenisation of defence procurement creates new opportunities for India's military industrial sector. The Government of India (GoI) has so far released five lists of items for positive indigenisation - these should be manufactured in India, rather than imported. Each item on these lists represents an opportunity for some local firm.
The Medicines and Healthcare Regulatory Agency, which had been formally tasked by the UK government last month with the process of clearance after the jab emerged "safe and effective" against the novel coronavirus in human trials, is expected to authorise the vaccine by December 28 or 29 after the final data is provided on Monday, 'The Daily Telegraph' quoted senior government sources as indicating.
"We have started the phase-III trials of the vaccine (candidate Covishield). We will administer dose to 150 to 200 volunteers," said Dr Muralidhar Tambe, Dean, Sassoon General Hospital.
'We seem to be in a situation where we can do little, and nothing needs to be done anyway.'
Two doses of Pfizer and AstraZeneca COVID-19 vaccines generate lower levels of antibodies against the Omicron variant of coronavirus, according to a study which suggests that those previously infected or vaccinated may be at an increased risk of infection.
Poonawalla, however, did not specify the quantity of the doses that will be kept for the community, which is grappling with a shrinking population.
The government should take measures to promote innovation and R&D while simplifying regulations for the sector in the upcoming Union Budget, as per pharmaceutical industry bodies. Outlining the wish list for the sector in the upcoming Union Budget, Indian Pharmaceutical Alliance (IPA) secretary general Sudarshan Jain said the domestic pharma industry is currently around $50 billion in size and aspires to grow to around $130 billion by 2030 and $450 billion by 2047. "To achieve this vision, the Union Budget 2023-2024 should help fuel innovation and R&D, which will set the pace for propelling the pharmaceutical industry forward," he told PTI.
'SII has started stockpiling the vaccine and now has roughly 40 million doses ready. It is using some of the capacities it had for under development products for the COVID-19 vaccine and by January we will have a capacity to make 100 million doses per month and a stockpile of 200 million doses.'
Serum Institute of India plans to make 300 million doses of AZD1222 by December, and will begin phase-2 trials soon. It has also tied up with Novavax for development and commercialisation of its candidate.
The technical advisory group will now meet on November 3 for a final assessment.
'Brahmastra is kind of a meeting place of modern India with a feeling of ancient Indian powers about it.'
While it is not clear whether the volunteer had received the vaccine or a placebo shot during the trial, Anvisa has refused to reveal any more information citing reasons of medical privacy, CNN reported.
Pune's Serum Institute of India, the world's largest vaccine maker by volume, is placing its bets on the Oxford-AstraZeneca vaccine candidate AZD1222 with CEO Adar Poonawalla stating he would start manufacturing at personal risk.
Serum Institute already has two deals of 100 million each to supply the Oxford-AstraZeneca and the Novavax vaccine to Gavi-Covax at $3 per dose.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances